Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for suppressing breast cancer cell in-vitro growth and treating breast cancer

A breast cancer cell, breast cancer technology, applied in the field of anticancer drugs, can solve the problem of no combined effect of arsenic trioxide and tetrandrine, and achieve the effect of reducing toxicity

Active Publication Date: 2009-05-06
裴晓华 +2
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no report on the combined effect of arsenic trioxide and tetrandrine, and there is no report on the combined use of arsenic trioxide and tetrandrine in the treatment of other tumors or other diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for suppressing breast cancer cell in-vitro growth and treating breast cancer
  • Medicine for suppressing breast cancer cell in-vitro growth and treating breast cancer
  • Medicine for suppressing breast cancer cell in-vitro growth and treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 Cell growth inhibition rate experiment

[0046] In this example, the human breast cancer cell line MCF-7 was used as the research object, and tetrandrine and arsenic trioxide were used alone and combined as processing factors. The cell growth inhibition rate experiment was used to observe whether synergy is produced, and to screen the concentration that produces synergy.

[0047] 1 Experimental method

[0048] 1.1 Grouping

[0049] This test is divided into two parts: A and B:

[0050] A: Choose five concentrations of tetrandrine 0.5ug / ml, 1ug / ml, 2ug / ml, 4ug / ml, 8ug / ml, and two concentrations of arsenic trioxide 0.375ug / mL and 0.75ug / mL for single and combined use. details as follows:

[0051]

[0052] B: Choose five concentrations of arsenic trioxide: 0.0469ug / mL, 0.0937ug / mL, 0.1875ug / mL, 0.375ug / mL, and 0.75ug / mL. Tetrandrine 2.5ug / mL and 3ug / mL are used alone and in combination. . details as follows:

[0053]

[0054] 1.2 Cell culture

[0055] MCF-7 cells w...

Embodiment 2

[0080] Example 2 Detection of cell apoptosis rate

[0081] 1 Experimental method

[0082] 1.1 Experiment grouping

[0083] The purpose of this example is to observe whether the two drugs induce apoptosis within the synergistic range. Therefore, the experiment is divided into a normal control group, an arsenic trioxide group, a tetrandrine group, and a combined drug group.

[0084] According to the results of Example 1 of this part, the drug concentration range that produces synergistic effects is selected, tetrandrine 3ug / ml and arsenic trioxide 0.1875ug / mL are selected for single use, and the two concentrations are selected for combined use.

[0085] 1.2 Cell culture

[0086] For MCF-7 cells in the logarithmic growth phase, adjust the cell concentration to 3×10 4 Pcs / ml, inoculate in 6-well culture plate, add 2ml cell suspension to each well, place at 37℃, 5% CO 2 Cultivate for 24h in an incubator. The culture medium was changed and divided into a control group and a different co...

Embodiment 3

[0098] Example 3 Observation of cell surface morphology by scanning electron microscope

[0099] 1 Experimental method

[0100] 1.1 Experiment grouping

[0101] The experiment was divided into normal control group, arsenic trioxide 0.1875ug / mL group, tetrandrine 3ug / ml group and combination medication group.

[0102] 1.2 Cell culture

[0103] Same as Example One

[0104] 1.3 Preparation and observation of scanning electron microscope specimens

[0105] In a sterile environment, detoxify the sterile coverslips, put them into the wells of the six-well plate, add 1ml of 1% (WPV) polylysine to each well, aspirate after 15 minutes, and remove the six wells. Dry the board for later use. For MCF-7 cells in the logarithmic growth phase, adjust the cell concentration to 1×10 5 Pcs / ml, inoculate in 6-well culture plate, add 2ml cell suspension to each well, place at 37℃, 5% CO 2 Cultivate for 24h in an incubator. The culture medium was replaced and divided into normal control group, arsenic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicament for curing breast cancer, which contains two components: arsenic trioxide and tetrandrine; the content of the tetrandrine is 5 to 40mg / ml; the content of the arsenic trioxide is 0.9 to 7.5mg / ml; the dosage of the tetrandrine is 5mg question mark kg<-1> question mark d<-> and the dosage of the arsenic trioxide is 0.3mg question mark kg<-1> question mark d<-1>; the components of the medicine also include fluorouracil and / or amylose. Another technical proposal of the invention is the medicament for inhibiting the in-vitro growth of breast cancer cells; and the content of the tetrandrine thereof is 0.5 to 4ug / ml and the content of the arsenic trioxide is 0.09 to 0.75ug / ml. The medicament for curing the breast cancer has the beneficial effects that the combined use of the arsenic trioxide and the tetrandrine can reduce the toxicity of the arsenic trioxide and the effect is better than that of independent medication; within the concentration range, the combined medication generates synergy which can be repeated; and if the concentration range is more or less than the concentration range, additive effect and even antagonism can be generated.

Description

Technical field [0001] The invention relates to the technical field of anticancer drugs, in particular to a drug for inhibiting breast cancer cell growth in vitro and treating breast cancer. Background technique [0002] There are different studies on the effects of arsenic trioxide and tetrandrine on human breast cancer cells in the prior art. For example, Zhang et al. (Zhang Lina, Wang Liuxing, Fan Qingxia, etc.) 2 O 3 Study on the effect of breast cancer cell line MDA-MB-435s[J].Chinese Journal of Misdiagnosis.2007,6,7(12):2688-2691) Study on the effect of different concentrations of arsenic trioxide on human breast cancer cell line MDA-MB-435s The growth inhibitory effect of As 2 O 3 Dose-dependent inhibition of cell growth, and typical changes in apoptosis morphology were observed; agarose gel electrophoresis showed apoptotic DNA ladder-like bands; As 2 O 3 The apoptosis index of the effect group was significantly higher than that of the negative control group (P<0.05). T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/36A61K31/4748A61P35/00A61K31/513A61K31/715
Inventor 裴晓华李曰庆樊英怡马秀璟李桃花
Owner 裴晓华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com